Fecal Incontinence - Pipeline Review, H1 2016

  • ID: 3635621
  • Drug Pipelines
  • 43 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celogos
  • Cook MyoSite Incorporated
  • Norgine B.V.
  • RDD Pharma Ltd.
  • MORE
Fecal Incontinence - Pipeline Review, H1 2016

Summary

The report ‘Fecal Incontinence - Pipeline Review, H1 2016’, provides an overview of the Fecal Incontinence pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fecal Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fecal Incontinence and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fecal Incontinence
- The report reviews pipeline therapeutics for Fecal Incontinence by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fecal Incontinence therapeutics and enlists all their major and minor projects
- The report assesses Fecal Incontinence therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fecal Incontinence

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celogos
  • Cook MyoSite Incorporated
  • Norgine B.V.
  • RDD Pharma Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Fecal Incontinence Overview

Therapeutics Development

Pipeline Products for Fecal Incontinence - Overview

Fecal Incontinence - Therapeutics under Development by Companies

Fecal Incontinence - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Fecal Incontinence - Products under Development by Companies

Fecal Incontinence - Companies Involved in Therapeutics Development

Celogos

Cook MyoSite Incorporated

Innovacell Biotechnologie AG

Juventas Therapeutics, Inc.

Norgine B.V.

RDD Pharma Ltd.

Fecal Incontinence - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ICEF-15 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

methoxamine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxymetazoline hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RCD-2 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Fecal Incontinence, Ischemic Heart Failure and Urological Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Fecal Incontinence - Recent Pipeline Updates

Fecal Incontinence - Dormant Projects

Fecal Incontinence - Product Development Milestones

Featured News & Press Releases

Jan 07, 2016: RDD Pharma Announces Additional Positive Results in a Double-Blind Placebo-Controlled Phase 2a Study in Fecal Incontinence

Oct 16, 2015: RDD Pharma Announces Positive Results in a Double-Blind Placebo-Controlled Crossover Phase 2a Study in Fecal Incontinence in Patients with Spinal Cord Injury

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Fecal Incontinence, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Fecal Incontinence - Pipeline by Celogos, H1 2016

Fecal Incontinence - Pipeline by Cook MyoSite Incorporated, H1 2016

Fecal Incontinence - Pipeline by Innovacell Biotechnologie AG, H1 2016

Fecal Incontinence - Pipeline by Juventas Therapeutics, Inc., H1 2016

Fecal Incontinence - Pipeline by Norgine B.V., H1 2016

Fecal Incontinence - Pipeline by RDD Pharma Ltd., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Fecal Incontinence Therapeutics - Recent Pipeline Updates, H1 2016

Fecal Incontinence - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Fecal Incontinence, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Celogos
Cook MyoSite Incorporated
Innovacell Biotechnologie AG
Juventas Therapeutics, Inc.
Norgine B.V.
RDD Pharma Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll